Health Care • Biotechnology: Pharmaceutical Preparations
$111.59 ▲ +14.61
(+15.07%)
MKT CAP: $24.37B • VOL: 11.22M
52W L $90 52W H $213
INSM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $606.4M | $363.7M | $305.2M |
| YoY Revenue Growth % | +66.7% | +19.2% | — |
| Gross Profit | $483.5M | $278.0M | $134.3M |
| Gross Margin % | 79.7% | 76.4% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.25B | -$878.3M | -$709.6M |
| Operating Margin % | -205.6% | -241.5% | -232.5% |
| Net Income (GAAP) | -$1.28B | -$913.8M | -$749.6M |
| EBITDA (Normalized) | -$1.22B | -$860.7M | -$698.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$935.0M | -$683.9M | -$536.2M |
| Capital Expenditures (CapEx) | $32.6M | $21.9M | $13.7M |
| Free Cash Flow (FCF) | -$967.6M | -$705.8M | -$550.0M |
| FCF Margin % | -159.6% | -194.1% | -180.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -6.9% |
| Cash & Short-Term Equivalents | $510.4M | $555.0M | $1.47B |
| Total Debt (Short + Long Term) | $541.0M | $1.10B | $3.14B |
| Total Stockholders' Equity | $739.0M | $285.4M | $6.43B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INSM.